{"id":"W4415013760","doi":"10.1016/j.ccell.2025.09.009","title":"Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial","year":2025,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"Key Research and Development Program of Zhejiang Province; National Key Research and Development Program of China; Science and Technology Department of Zhejiang Province; Natural Science Foundation of Jiangxi Province; National Natural Science Foundation of China","keywords":"FOLFIRINOX; Gemcitabine; Hazard ratio; Regimen; Clinical endpoint; Neoadjuvant therapy; Confidence interval; Adverse effect; Adjuvant","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001307621,0.000394708,0.002547781,0.0001761256,0.0002607006,0.00004432233,0.0002842447,0.0003066825,0.001034449],"category_scores_gemma":[0.0008845517,0.0003114637,0.0005249053,0.0004085556,0.0003107942,0.0001078771,0.00008550205,0.0003530785,0.00001423489],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001226045,"about_ca_system_score_gemma":0.002967006,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005840122,"about_ca_topic_score_gemma":0.0003697369,"domain_scores_codex":[0.9967153,0.0002871046,0.0009045284,0.0007037111,0.000443887,0.0009454897],"domain_scores_gemma":[0.9967063,0.001692569,0.0002404322,0.0006308561,0.0003746017,0.0003552619],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8247163,0.0007896778,0.0003222176,0.0008433312,0.0009926861,0.00002436028,0.0003796718,0.00002077286,0.0100231,0.0003277351,0.1590344,0.002525738],"study_design_scores_gemma":[0.9392086,0.001333979,0.00001416579,0.0004119374,0.002742693,0.000002251446,0.0001607217,0.01953446,0.005854685,0.0007176768,0.02972523,0.0002936232],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8604442,0.0627003,0.009679553,0.004620927,0.001638722,0.01444503,0.0004985103,0.0001653444,0.0458074],"genre_scores_gemma":[0.7563964,0.01157467,0.001265085,0.001504765,0.000829483,0.0190473,0.0002523092,0.00008846974,0.2090416],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1632342,"threshold_uncertainty_score":0.9999337,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03838965553033384,"score_gpt":0.4005066183083725,"score_spread":0.3621169627780386,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}